/
OTLK
$1.69-$0.02 (-1.17%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$254.1M
149M shares
52-week range
$0.16 – $3.39
47% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
17.69%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-48.11
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.1M | $8.1M | $0 | $0 | $0 | $0 | $0 | $1.4M |
| Cost of revenue | $18.5M | $23.8M | $554.1K | $262.1K | $204.7K | $44.2K | $113.9K | $756.3K |
| Gross profit | $0 | −$15.7M | −$554.1K | −$262.1K | −$204.7K | −$44.2K | −$113.9K | $657.2K |
| Gross margin | 0.0% | -192.2% | — | — | — | — | — | 46.5% |
| R&D | $18.5M | $23.8M | $26.3M | $39.0M | $42.3M | $26.5M | $41.8M | $27.18T |
| Operating income | −$29.6M | −$36.3M | −$36.8M | −$51.7M | −$63.1M | −$53.1M | −$71.7M | −$67.1M |
| EBITDA | −$26.8M | −$31.1M | −$36.2M | −$51.5M | −$64.4M | −$57.4M | −$72.1M | −$63.6M |
| Net income | −$30.1M | −$34.5M | −$35.2M | −$53.2M | −$66.1M | −$59.0M | −$75.4M | −$62.4M |
| Net margin | -974.5% | -423.8% | — | — | — | — | — | -4416.2% |
| EPS (diluted) | -85.00 | -39.60 | -13.47 | -6.96 | -6.23 | -4.72 | -4.06 | -1.79 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $14M | $-0.49 | $-0.52–$-0.43 | 1 |
| 2027 | $46M | $-0.23 | $-0.34–$-0.12 | 3 |
| 2028 | $23M | $-0.15 | $-0.45–$-0.02 | 1 |
| 2029 | $30M | $-0.12 | $-0.36–$-0.01 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.39
Price
$1.69
Implied downside
-77%
Peer comparison
Outlook Therapeutics, Inc. Common Stock
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
www.outlooktherapeutics.com- Employees
- 17
- IPO / List date
- May 13, 2016
- HQ
- ISELIN, NJ
Held by traders on TradeandTell
No one on the platform currently holds OTLK.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 255,157 | $52.5K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-03-14 | 1-for-20reverse |
| 2019-03-18 | 1-for-8reverse |
Recent trades on TradeandTell
No one on the platform has traded OTLK yet.
